News

Major success for T-DM1
Enlarge image

Clinical TrialsSwitzerlandAustria

Major success for T-DM1

02.10.2012 - Roche's trastuzumab emtansine (T-DM1) appears to keep its promises. The armed antibody significantly extended overall survival in breast cancer patients.

Roche presented the latest big pack of Phase III data for T-DM1 at the ESMO conference currently being held in Vienna. The EMILIA study has shown that people with previously treated HER2-positive metastatic breast cancer survived significantly longer when treated with T-DM1 compared to those who received the standard-of-care, a combination of lapatinib and capecitabine. Results showed the risk of death was reduced by 32% for people who received the antibody-drug conjugate compared to those who received lapatinib plus Xeloda (HR=0.68; P=0.0006). People in the study treated with trastuzumab emtansine survived a median of 5.8 months longer than those who received lapatinib and Xeloda  (median overall survival: 30.9 months vs. 25.1 months). No new safety signals were observed and adverse events (AEs) were consistent with those seen in previous studies, with fewer people who received trastuzumab emtansine experiencing Grade 3 or higher (severe) adverse events than those who received lapatinib plus Xeloda (40.8 percent vs. 57.0 percent).

Representatives from Roche and industry experts were "extremely pleased" with the results. "Roche is moving away from Herceptin, with successors that are not just an inch better, but much, much better," said Andrew Weiss from Vontobel. Simos Simeonidis from SG Cowen has laid out a bullish marketing scenario, expecting that T-DM1 could earn more than its predecessor Herceptin (US$5.4bn) last year. "And since it will probably be priced at a meaningful premium to Herceptin, we think T-DM1 could end up as one of the biggest biotech drugs", Simeonidis said.

Genentech Inc., a Roche subsidiary situated in San Francisco (USA), is the developer of T-DM1. The company has already filed a marketing application for the drug to the Food and Drug Administration (FDA) in the US. The development was accomplished under an agreement with ImmunoGen, Inc. from Waltham (USA). The company from Massachusetts provides the linker chemistry and the compound drug's cancer killing agent, which is targeted by the antibody (trastuzumab) to Her2neu tumour cell receptors. ImmunoGen calls its technology TAP, Targeted Antibody Payload. The cytotoxic agent is a derivative of maytansine that inhibits the assembly of microtubules. Maytansines are potent toxins that naturally occur in the shrubs and trees of the Genus Maytenus spp.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/major-success-for-t-dm1.html

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%

FLOP

  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%

TOP

  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%

TOP

  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%

FLOP

  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014